Perrigo is one of the largest consumer health companies in the world. Since 2018, Perrigo divested its animal health and generic pharmaceuticals businesses to solely focus on consumer self-care. In North America (two thirds of total sales), the firm’s product mix is anchored in private-label consumer health goods, which are sold to major retailers like Walmart, Amazon, Costco, and CVS. Perrigo also plays in Europe, Australia, and parts of Asia where it primarily generates revenue through its national brands, including Compeed, Solpadeine, Coldrex, and ellaOne.

Perrigo, founded in 1887, is a leading manufacturer of generic over-the-counter healthcare products and supplier of infant formulas for the store-brand market. Perrigo's private-label consumer products encompass a variety of cold/allergy, gastrointestinal, first aid, motion sickness, vitamin, smoking cessation, and other remedies. The company has a market cap of approximately $4 billion after divesting its RX pharmaceutical business in 2021. Headquartered in Dublin, Ireland, Perrigo has over 9,100 employees. The shares are a component of the S&P 400 Mid-Cap Index.

Nasdaq, we have a problem. Stocks started the year with some difficult sledding -- and the action after the nonfarm payrolls report blew away expectations (suggesting more near-term Fed stimulus may be a fading dream) was particularly awful. Now, insiders have weighed in. And ugh. The one-week sell/buy ratio from Vickers Stock Research for the NYSE has broken into negative territory, at 6.25 on a scale were anything above 6.00 is bearish. Last week, the ratio was 3.38. That's not great, but it is only a single week (so far). But the one-week ratio for the Nasdaq also moved into negative territory since last week - and it is here that we really take notice, as the current ratio is an eye-popping 15.57 compared to 4.54 last week. That is an ominous number under any circumstances, but we especially hate to see it just as earnings season is starting and with insiders mostly prohibited from trading for multiple weeks. Indeed, these ratios are not the 'final word' we wanted from corporate executives, directors, and beneficial owners. On a sector basis, insider buying was the greatest in the Industrials sector over the last week, with shares valued at $3.4 million bought versus $5.9 million sold for a sell/buy ratio of 1.8. The sell/buy ratio was also largely bullish in the Financial sector during the past week, coming in at 1.7 (although the overall value of transactions was lower than in the Industrials sector). Meanwhile, selling was the greatest in Information Technology over the last week, with shares valued at $186 million sold versus no shares bought. See above! This week, analysts at Vickers highlighted insider transactions of interest at CNX Resources Corp. (NYSE: CNX) and Broadcom Inc. (NGS: AVGO).

Perrigo is one of the largest consumer health companies in the world. Since 2018, Perrigo divested its animal health and generic pharmaceuticals businesses to solely focus on consumer self-care. In North America (two thirds of total sales), the firm’s product mix is anchored in private-label consumer health goods, which are sold to major retailers like Walmart, Amazon, Costco, and CVS. Perrigo also plays in Europe, Australia, and parts of Asia where it primarily generates revenue through its national brands, including Compeed, Solpadeine, Coldrex, and ellaOne.